Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Indaptus Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 19 | 5 | −14 |
| Shares | 687.0K | 307 | −686.7K (−100.0%) |
| Value | $377.8K | $3.23K | −$374.5K (−99.1%) |
New holders (1)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 10 | $105 | 0.00% |
Sold out (15)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Vanguard Group Inc | 256,265 | $140.9K |
| Investment House LLC | 128,851 | $70.9K |
| Geode Capital Management, LLC | 124,967 | $68.7K |
| Strategy Asset Managers LLC | 45,336 | $24.9K |
| Pine Valley Investments Ltd Liability Co | 43,771 | $24.1K |
| Renaissance Technologies LLC | 28,500 | $15.7K |
| Vivaldi Capital Management, LLC | 24,000 | $13.2K |
| State Street Corp | 13,073 | $7.19K |
| Virtu Financial LLC | 12,872 | $7.00K |
| Morgan Stanley | 884 | $486 |
| Bangor Savings Bank | 350 | $192 |
| UBS Group AG | 87 | $49 |
| JPMorgan Chase & Co | 17 | $9 |
| Group One Trading, L.P. | 7 | $4 |
| Danske Bank A/S | 1 | $1 |